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Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. 
For the treatment of HCC, although many different kinds of treatment are performed 
according to the practical guidelines, the prognosis of patients is not still satisfactory 
because the effects of treatments are limited for advanced tumor and the recurrence rate 
of HCC, even in early stages, is very high. Therefore, immunotherapy is strongly 
anticipated as a new treatment method for HCC. For the development of new HCC 
therapy, we attempted to establish immunotherapy using dendritic cells (DC) and 
peptide vaccine. In several clinical trials that we performed, we confirmed that the 
immunotherapy was safe and well tolerated by HCC patients. We observed that DC 
therapy prolonged the recurrence-free survival of patients compared with that of 
patients without DC infusion, as well as the radiological anti-tumor effect in HCC 
patients with peptide vaccine. In this chapter, we summarize the results of previous 
studies using DC and peptide vaccine, including our own data, and describe the 
prospects of immunotherapy for HCC. 
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1.1  Introduction 
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer 
globally. Annually, more than 550,000 people die due to HCC (El-Serag and Rudolph 
2007; Parkin 2001), about 35,000 of whom are from Japan. The main risk factor of 
HCC is chronic liver disease, such as chronic hepatitis or liver cirrhosis caused by 
hepatitis B (HBV) or C virus (HCV). Recently, metabolic abnormalities, such as 
diabetes, obesity, and fatty liver, have been determined to be risk factors of HCC; in 
association with this, HCC has been increasing in Western and Asian countries and has 
become a serious health issue.  
For the treatment of HCC, many different kinds of treatment, such as surgical 
resection, liver transplantation, radiofrequency ablation (RFA), transarterial 
chemoembolization (TACE), chemotherapy and sorafenib, are performed according to 
the practical guidelines (El-Serag et al. 2008). Although these treatments have been 
performed for HCC, their effects are limited and the recurrence rate of HCC is very high. 
Since HCC arises from an injured hepatocyte, recurrence occurs at a high rate, even 
when the existing tumor is removed, unless the background liver disease is completely 
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cured. Moreover, patients who have already developed HCC are mostly in an advanced 
stage at the time of diagnosis, so it is difficult for them to receive curative treatment.  
Therefore, new treatments are needed to improve the outcome of HCC patients; 
these include treatment to prevent recurrence after curative treatment and treatment for 
advanced HCC exhibiting an anti-tumor effect through a mechanism different from 
those of existing treatments. In this regard, immunotherapy is strongly anticipated as a 
new treatment method for HCC. For the development of new HCC therapy, we have 
tried to establish immunotherapy using dendritic cells (DCs) and peptide vaccine. 
 
1.2  Dendritic cell therapy 
For the development of immunotherapy for HCC, we first undertook an 
analysis of the host anti-tumor immunological status in patients with HCC. In this basic 
study, we identified some tumor-associated antigens (TAAs) and their cytotoxic T-cell 
(CTL) epitope to which T cells in peripheral blood mononuclear cells (PBMCs) of HCC 
patient responded (Mizukoshi et al. 2006; Mizukoshi et al. 2006; Mizukoshi et al. 2008; 
Mizukoshi et al. 2011; Mizukoshi et al. 2012). Next, we developed methods to prepare 
the DCs from the PBMCs of an HCC patient and to deliver the DCs to a local tumor site 
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(Nakamoto et al. 2007). Using these methods and HCC-associated TAA-derived epitope, 
we investigated the safety and immunological effect of DC immunotherapy in patients 
with HCC. 
In the first clinical trial, DCs were injected to a local tumor site using an 
arterial catheter in patients who had HCC and had been treated with transarterial 
embolization (TAE) (Nakamoto et al. 2007). DCs were prepared as follows. PBMCs 
were plated in six-well tissue culture dishes and allowed to adhere to the plastic for 2 h. 
Adherent cells were then cultured with 1000 U/ml recombinant human interleukin 
(IL)-4 and 100 ng/ml recombinant human granulocyte macrophage colony-stimulating 
factor (GM-CSF) for 7 days. On day 7, the cells were harvested. Then, 5 X 106 cells 
were reconstituted in 5 ml of normal saline containing 1% autologous plasma, mixed 
with absorbable gelatin sponge and infused through an arterial catheter following 
Lipiodol injection during selective TAE therapy. 
In this clinical trial, we identified the following phenomena: 1) DC infusion is 
associated with no clinical or serological evidence of adverse events, including hepatic 
failure or autoimmune responses, in addition to those due to TAE alone. 2) Following 
the infusion of 111indium-labeled DCs, DCs were detectable inside and around the HCC 
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nodules for up to 17 days. 3) T-lymphocyte responses were induced against peptides 
derived from some tumor antigens, human epidermal growth factor receptor 2 
(Her-2/neu), multiple drug resistance-associated protein (MRP) 3, human telomerase 
reverse transcriptase (hTERT) and alpha-fetoprotein (AFP) in some patients. 4) The 
cumulative survival rates were not significantly changed by this strategy. On the basis 
of these results, we conclude that transcatheter arterial DC infusion into tumor tissues 
following TAE treatment is feasible and safe for patients with cirrhosis and HCC. 
Furthermore, the antigen-non-specific, immature DC infusion may induce immune 
responses to unprimed tumor antigens, providing a plausible strategy to enhance tumor 
immunity. 
In the next step, we designed a clinical trial to examine the protective effect of 
DC therapy for HCC recurrence after local treatment (Nakamoto et al. 2011). In this 
study, we used DCs pulsed with OK-432, which is a streptococcus-derived anti-cancer 
immunotherapeutic agent, and identified the following phenomena: 1) OK432 
stimulation of immature DCs promoted their maturation towards cells with activated 
phenotypes, high expression of a homing receptor, fairly well-preserved phagocytic 
capacity, greatly enhanced cytokine production and effective tumoricidal activity. 2) 
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Administration of OK432-stimulated DCs to patients was feasible and safe. 3) 
Administration of OK432-stimulated DCs prolonged recurrence-free survival of 
patients compared with that of patients without DC infusion. 4) The bioactivity of the 
transferred DCs was reflected in higher serum concentrations of the cytokines IL-9, 
IL-15 and tumor necrosis factor-α and the chemokines CCL4 and CCL11. On the basis 
of these results, we conclude that a DC-based, active immunotherapeutic strategy in 
combination with loco regional treatments exerts beneficial anti-tumor effects against 
HCC. 
In addition to our studies, several immunotherapies using DCs have been 
reported in patients with HCC (Table 1) (Ladhams et al. 2002; Iwashita et al. 2003; Stift 
et al. 2003; Lee et al. 2005; Chi et al. 2005; Butterfield et al. 2006; Palmer et al. 2009; 
Zhou et al. 2011; Qiu et al. 2011; Tada et al. 2012). Most of these used DCs generated 
ex vivo from the peripheral blood of the patient, pulsed with tumor lysate or 
TAA-derived peptides. These studies have shown that DC therapy is safe and well 
tolerated in HCC patients. They have also indicated that tumor-specific immune 
response is induced by DC infusion, and an anti-tumor effect consisting of prolonged 
recurrence-free survival after treatment and overall survival is observed in some cases. 
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In several studies, partial radiological response is also observed. However, the strength 
of the anti-tumor effect and the frequency of patients who have a clinical benefit are still 
not satisfactory. To establish a treatment using DCs as an immunotherapy for HCC, 
further clinical trials are necessary to prove the clinical efficacy in more patients with 
HCC. 
 
1.3  Peptide vaccine 
In addition to DC therapy, we also attempted to develop peptide vaccine as an 
immunotherapy for HCC. The first step to establish the treatment is identification of 
TAA expressed in HCC. Since HCC is complicated by background liver damage in 
many cases, the establishment of a safe and effective peptide vaccine for HCC depends 
on whether an immune response killing only tumor cells without injuring normal 
hepatocytes can be induced, for which it is necessary to discover HCC-specific TAA 
with high-level immunogenicity. Generally, HCC had not been considered as an 
“immunogenic” tumor, but previous studies reported that the risk of recurrence after 
treatment was low and the outcome was favorable in HCC patients with many 
infiltrating lymphocytes in the tumor, suggesting that anti-tumor immunity is also 
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present and tumor progression is inhibited through an immunological mechanism in 
HCC patients (Wada et al. 1998). Actually, including our data, many TAAs and their 
CTL epitope expressed in HCC have been discovered over the past 10-15 years 
(Butterfield et al. 2001; Zerbini et al. 2004; Korangy et al. 2004; Komori et al. 2006; 
Mizukoshi et al. 2006; Mizukoshi et al. 2006).       
However, to date, there have been no reported studies of T-cell responses to 
previously identified TAAs or their epitopes being measured simultaneously and 
comparatively in many HCC patients. Therefore, to identify suitable epitopes for 
peptide vaccine, we performed a simultaneous and comparative analysis of immune 
responses to 27 different CTL epitopes derived from 14 previously reported TAAs in the 
PBMCs of 31 HCC patients (Mizukoshi et al. 2011). In this study, we made the findings 
and selected suitable epitopes: 1) The TAAs consisting of cyclophilin B, squamous cell 
carcinoma antigen recognized by T cells (SART) 2, SART3, p53, MRP3, AFP and 
hTERT were frequently recognized by T cells and these TAA-derived peptides were 
capable of generating peptide-specific CTLs in HCC patients, which suggested that 
these TAAs are immunogenic. 2) HCC treatments enhanced TAA-specific immune 
responses with an increased number of memory T cells and induced de novo T-cell 
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On the basis of the above data, we are now conducting several clinical trials on 
HCC patients using hTERT-, AFP-, MRP3-, SART2- and SART3-derived peptides. In 
the clinical trial of hTERT-derived peptide vaccine, HCC patients treated by RFA were 
enrolled. The peptide was administered emulsified with incomplete Freund’s adjuvant 
by subcutaneous immunization 3 times biweekly. The maximum toxicity observed was 
grade 2 according to the common terminology criteria and mainly consisted of skin 
reactions at the vaccination sites. Several immunological assays revealed that the 
vaccination induced hTERT-specific immunity. Although the HCC recurrence-free 
survival time after RFA did not differ between patients without vaccination and those 
with the hTERT-specific immune response after vaccination, the recurrence rate in 
patients with vaccination was reduced beyond one year after RFA. 
In the clinical trial of AFP-derived peptide vaccine, advanced HCC patients, 
who had been treated by standard therapy including surgical resection, RFA, TACE, 
chemotherapy and sorafenib but did not show a clinical benefit, were enrolled. The 
method of vaccination was almost the same as that for hTERT-derived peptide vaccine, 
but it was continued until the confirmation of tumor progression. The observed toxicity 
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mainly consisted of skin reactions at the vaccination sites, and severe adverse events 
were not observed. To date, we have observed one patient with complete response (CR) 
and one patient with long-term stable disease (SD). AFP-specific immune responses 
were observed in these 2 patients by several immunological assays. These results are 
encouraging for the possibility of using peptide vaccines for HCC. 
Regarding an immunotherapy using peptide vaccines for HCC, several studies 
have been reported (Table 2) (Butterfield et al. 2003; Greten et al. 2010; Sawada et al. 
2012). A clinical trial of HCC immunotherapy using AFP-derived peptides has been 
performed, in which AFP-specific CTL increased after treatment in 6 of 6 HCC patients. 
In addition to AFP, clinical trials of vaccines comprised of the CTL epitopes of hTERT 
and GPC3 involving HCC patients have been performed (Greten et al. 2010; Sawada et 
al. 2012). hTERT-derived peptide vaccine was administered in combination with 
cyclophosphamide to 40 patients with advanced HCC, but no potentiation of immune 
reactions to the peptide was observed, and, regarding the anti-tumor effect, no patient 
showed a CR or partial response (PR) (Greten et al. 2010). In the clinical trial of 
GPC3-derived peptide, vaccine was administered to 33 advanced HCC patients (Sawada 
et al. 2012). A partial response was noted in one patient, and an effect maintaining an 
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SD condition for more than 2 months was noted in 19 patients. In addition, tumor 
necrosis and size reduction were noted in 4 of the 19 patients in whom the disease 
condition was stabilized, supporting the possibility of using TAA-targeting 
immunotherapy for HCC. No serious adverse events occurred in AFP-, hTERT-, or 
GPC3-targeted immunotherapy, confirming that immunotherapy by peptide vaccine can 
be safely applied in advanced HCC patients with reduced hepatic reserve capacity.  
 
1.4  Prospects of immunotherapy for hepatocellular carcinoma 
In previous studies, including our own, the anti-tumor effect induced by 
immunotherapy for HCC was not so strong and frequent. Several mechanisms have 
been considered as reasons for the insufficient anti-tumor effect of cancer 
immunotherapy. Similarly to other cancer types, HCC has a mechanism to escape from 
host immune responses. In particular, the presence and mechanism of cells leading 
immune responses in the negative direction, such as regulatory T cells (Tregs) and 
myeloid-derived suppressor cells (MDSCs), in HCC have recently been clarified. Tregs 
are the most strongly characterized suppressor cells shown to inhibit anti-tumor 
immunity in many studies. Increased Tregs in PBMCs and tumor-infiltrating 
13 
Mizukoshi et al.  Development of immunotherapy for hepatocellular carcinoma 
 
 
lymphocytes (TILs) in HCC patients have been reported (Unitt et al. 2005). In a study in 
which low-dose cyclophosphamide was administered to eliminate Tregs in advanced 
HCC patients, the frequency and function of peripheral blood Tregs were reduced and 
AFP-specific T-cell reactions resumed (Greten et al. 2010).  
MDSCs have been reported to induce Foxp3 and IL-10 through the arginase 
activity in CD4+ T cells and to inhibit T-cell function through the induction of Tregs 
(Hoechst et al. 2008). A recent study reported that CD14+HLA-DR-/low MDSCs were 
increased in the peripheral blood of HCC patients and negatively correlated with 
TAA-specific T-cell responses (Mizukoshi et al. 2012). Unfortunately, no drug or 
antibody directly inhibiting this function of MDSCs is available, but elucidation of the 
detailed T-cell-inhibitory mechanism of MDSCs and elimination of this inhibition may 
lead to the potentiation of anti-tumor immunity.  
It is known that the inhibition of T-cell-induced anti-tumor immunity is also 
exhibited through inhibitory receptors. The typical molecules are cytotoxic 
T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1). These molecules 
transmit inhibitory signals to T cells by binding to specific ligands present on the 
surface of antigen-presenting or cancer cells and inhibit T-cell functions, such as 
14 
Mizukoshi et al.  Development of immunotherapy for hepatocellular carcinoma 
 
 
proliferation, cytokine secretion, and cytolysis. Many study results support the assertion 
that potent anti-tumor immunity can be achieved by inhibiting this T-cell-inhibitory 
system using an antibody. Currently, ipilimumab and tremelimumab are available as 
CTLA-4 antibodies. Ipilimumab has been approved as the first-line treatment for 
melanoma patients with metastasis (Robert et al. 2011; Ribas 2010). Regarding PD-1, in 
immunotherapy using an antibody against PD-1 and a ligand of PD-1 (PD-L1), 
objective responses (CR or PR) were observed in patients with treatment-refractory 
metastatic solid tumors (melanoma, renal-cell cancer, non-small-cell lung cancer, and 
ovarian cancer) (Topalian et al. 2012; Brahmer et al. 2012). At present, no clinical data 
on these antibodies from a large number of HCC cases have been reported, but they will 
appear in the future.  
As described above, recent studies on anti-tumor immunity have contributed to 
a marked advancement, and further development is expected in the field of HCC 
immunotherapy. In particular, there are high expectations for the development of a 
combination treatment method using DCs, peptide vaccines and immune-modulating 
antibodies to treat advanced HCC. To develop a new effective immunotherapy for HCC, 
it is necessary to establish the method of DC therapy, identify a highly immunogenic 
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HCC-specific TAA-derived T-cell epitope and elucidate the anti-tumor 
immunity-inhibitory mechanism of HCC.  
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Table 1 Clinical trials of DC therapies for HCC  
Year Author No. of Patients Setting for DCs Responses 
2002 Ladhams et al. 2 GM/IL-4 DC + tumor 1/2 inhibition of tumor growth 
2003 Iwashita et al. 10 GM/IL-4 DC + tumor 
lysate  + TNF-α + KLH 
1/10 MR 
2003 Stift et al. 2 GM/IL-4 DC + tumor 
lysate  + TNF- α + IL-2 
no PR or CR 
2005 Mazzolini et al. 8 GM/IL-4 DC + tumor + 
adenovirus IL-12 
2/8 SD 
2005 Lee et al. 31 DC + tumor lysate improved survival 
2005 Chi et al. 14 Radiotherapy + DC immune response 
2006 Butterfield et al. 10 DC with AFP peptides  no PR or CR 
2007 Nakamoto et al. 10 TAE + GM/IL-4 DC immune response 
2009 Palmer et al. 35 GM/IL-4 DC + HepG2 
cells lysate + TNF- α 
25 patients were assessed, 
1/25 PR and 6/25 SD 




2011 Zhou et al. 10 PMWA + GM/IL-4 DC + 
CIK + CTL 
immune response 
2011 Qiu et al. 9 GM/IL-4 DC + 
TNF- α + tumor lysate 
contained α-Gal epitope 
3/9 PR and 3/9 SD 
2012 Tada et al. 5 GM/IL-4 DC + 
recombinant protein (AFP, 
GPC3, MAGE-1) + 
cytokine cocktail 
1/5 SD 
2012 Ansary et al. 15 GM/IL-4 DC + HepG2 
cells lysate 
2/15 PR and 9/15 SD 
GM-CSF, granulocyte-macrophage colony stimulating factor; DC, dendritic cell; HCC, 
hepatocellular carcinoma; IL, interleukin; TNF, tumor-necrosis factor; KLH, keyhole 
limpet hemocyanin; TAE, transarterial embolization; PMWA, percutaneous microwave 
ablation; CIK, cytokine-induced killer cell; CTL, cytotoxic T lymphocyte; AFP, 
alpha-fetoprotein; GPC3, glypican-3; MAGE, melanoma-associated antigen; MR, 
mixed response; CR, complete response; PR, partial response; SD, stable disease 
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Table 2 Clinical trials of peptide vaccines for HCC 
Year Author No. of Patients Setting for peptides Responses 
2003 Butterfield et al. 6 AFP-derived peptides + 
Montanide adjuvant, 
HLA-A2 
no PR or CR 
2010 Greten et al. 40 hTERT-derived peptides  
+ cyclophosphamide + 
GM-CSF 
no PR or CR 
2012 Sawada et al. 33 GPC3-derived peptides + 
Montanide adjuvant, 
HLA-A24 and A2 
1/33 PR and 19/33 SD 
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survival and immune 
response 
2012 Mizukoshi et 
al.* 
20 AFP-derived peptides + 
Montanide adjuvant, 
HLA-A24 
15 patients were assessed, 
1/15 CR and 8/15 SD 
GM-CSF, granulocyte-macrophage colony stimulating factor; HCC, hepatocellular 
carcinoma; AFP, alpha-fetoprotein; hTERT, human telomerase reverse transcriptase; 
GPC3, glypican-3; SART2, squamous cell carcinoma antigen recognized by T cells 2; 
CR, complete response; PR, partial response; SD, stable disease; *, present study 
 
